Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
March 06 2018 - 7:30AM
Business Wire
Advances Strategy to Become a Leader in Global
Cellular Immunotherapy
Immediately Adds Late-Stage Therapy JCAR017, an
Expected Growth Driver From 2020 and Beyond with Potential Global
Peak Sales of Approximately $3B
Celgene Corporation (NASDAQ:CELG) today announced that it has
completed the acquisition of Juno Therapeutics, Inc. As a result,
the common stock of Juno will no longer be listed for trading on
the NASDAQ Global Select Market.
The Juno acquisition positions Celgene as a leading cellular
immunotherapy company by adding novel technology and advanced
cellular manufacturing capabilities to its broad commercial
portfolio and pipeline of therapies addressing serious unmet needs
in hematology and oncology. Celgene also gains full global rights
to JCAR017 (lisocabtagene maraleucel; liso-cel), a potentially
best-in-class CD-19 targeted CAR T therapy currently in pivotal
trials for relapsed and/or refractory diffuse large B-cell lymphoma
(DLBCL). Celgene expects the addition of JCAR017 and other cellular
immunotherapy products in Juno’s pipeline to accelerate revenue
diversification with meaningful growth drivers from 2020 and
beyond.
“Our colleagues at Juno are developing some of the most
promising approaches to treating cancer, and we are excited to add
their pioneering work to Celgene’s leading hematology and oncology
research and commercial platform,” said Mark J. Alles, Chairman and
Chief Executive Officer of Celgene. “Together, we expect to expand
our opportunities to discover and develop new therapies that will
improve and extend the lives of patients worldwide.”
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and
YouTube.
Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.
Forward-Looking Statement
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180306005858/en/
CelgeneInvestors:908-673-9628ir@celgene.comorMedia:908-673-2275media@celgene.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024